par Piccart-Gebhart, Martine
Référence Clinical breast cancer, 8 Suppl 3, page (S100-S113)
Publication Publié, 2008-03
Article révisé par les pairs
Titre:
  • Circumventing de novo and acquired resistance to trastuzumab: new hope for the care of ErbB2-positive breast cancer.
Auteur:Piccart-Gebhart, Martine
Informations sur la publication:Clinical breast cancer, 8 Suppl 3, page (S100-S113)
Statut de publication:Publié, 2008-03
Sujet CREF:Sciences bio-médicales et agricoles
MeSH keywords:Antibodies, Monoclonal -- therapeutic use
Antineoplastic Agents -- therapeutic use
Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
Breast Neoplasms -- drug therapy
Breast Neoplasms -- metabolism
Clinical Trials as Topic
Drug Resistance, Neoplasm -- physiology
Female
Humans
Receptor, erbB-2 -- drug effects
Receptor, erbB-2 -- metabolism
Note générale:Journal Article
Review
Langue:Anglais
Identificateurs:urn:issn:1526-8209
info:pmid/18777949